{"id":46544,"date":"2026-04-09T15:25:55","date_gmt":"2026-04-09T15:25:55","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/46544\/"},"modified":"2026-04-09T15:25:55","modified_gmt":"2026-04-09T15:25:55","slug":"roche-diagnostics-launches-new-glucose-monitoring-device-for-predicting-overnight-hypoglycemia-in-uk","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/46544\/","title":{"rendered":"Roche Diagnostics launches new glucose monitoring device for predicting overnight hypoglycemia in UK"},"content":{"rendered":"

Roche Diagnostics<\/a> has announced that its Accu-Chek SmartGuide continuous glucose monitoring (CGM) system is now reimbursable on the NHS, giving adults with diabetes easier access to the technology. The first NHS organisations to offer the device include Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board, and NHS Somerset Integrated Care Board.<\/p>\n

This decision makes it the first\u00a0artificial intelligence (AI)-driven CGM in the UK capable of predicting nighttime hypoglycaemia<\/a>.<\/p>\n

Using AI, the system analyses glucose patterns to forecast levels over the next 30 minutes, two hours and throughout the night, and prompts users to take action if their glucose is expected to drop below a safe range. A water-resistant sensor worn on the back of the upper arm sends readings to a smartphone app every five minutes, helping people stay informed and take action before low blood sugar becomes a problem.<\/p>\n

Around 5.6 million people in the UK are living with diabetes<\/a>, and while continuous glucose monitoring has\u00a0transformed care<\/a>\u00a0in recent years,\u00a0many still struggle to keep their blood sugar within a healthy range<\/a>. Low blood sugar episodes, known as hypoglycaemia, are\u00a0particularly common in people with type 1 diabetes<\/a>\u00a0and can be especially dangerous during sleep, when warning signs may go unnoticed.<\/p>\n

Research suggests<\/a>\u00a0that between 2\u20135% of deaths in people under 40 with type 1 diabetes are linked to nighttime hypoglycaemia, making early detection and prevention critical.<\/p>\n

Holli Gamewell, 24, was diagnosed with type 1 diabetes last November and was among the first patients to receive the new system on the NHS in January.<\/p>\n

Reflecting on the impact, she said: \u201cIt\u2019s made a big difference. I get a notification if my glucose level is going to go low, so then I can actually prevent the hypo. Just before I go to bed, it tells me if I\u2019m going to have a low overnight. I can have a snack before bed and then I\u2019m usually fine.\u201d<\/p>\n

The technology has also enabled Holli, from Salford, Greater Manchester, to continue working in her caf\u00e9 job, where she is sometimes the only person on shift. She added: \u201cHaving the prediction features means that I can comfortably do a job where I\u2019m on my own, and I don\u2019t have to worry.\u201d<\/p>\n

Peter Hampson, Head of Medical Affairs at Roche Diagnostics UK & Ireland said: \u201cFor many people living with diabetes, the fear of blood sugar dropping overnight is a constant worry. This technology helps remove some of that uncertainty by predicting potential lows before they happen, giving people greater confidence and peace of mind in their day-to-day lives. Roche Diagnostics is incredibly proud to be helping people feel safer and more in control of their diabetes.\u201d<\/p>\n

Clinical studies<\/a>\u00a0show the device delivers high accuracy, with 99.8% of readings falling within clinically acceptable ranges. The\u00a0evaluation<\/a>\u00a0of the predictive capabilities showed that all advanced predictive features exceeded high-performance requirements, e.g., accuracy, sensitivity, and specificity.<\/p>\n

Like this:<\/p>\n

Like Loading…<\/p>\n

<\/p>\n

\n\tRelated<\/p>\n","protected":false},"excerpt":{"rendered":"Roche Diagnostics has announced that its Accu-Chek SmartGuide continuous glucose monitoring (CGM) system is now reimbursable on the…\n","protected":false},"author":2,"featured_media":46545,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[2252,3495,14615,134,2057],"class_list":["post-46544","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-ai","tag-medical-devices","tag-nhs","tag-roche","tag-roche-diagnostics"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116375452687474636","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/46544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=46544"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/46544\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/46545"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=46544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=46544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=46544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}